nach oben

Erschienen in:

12.12.2015 | Original Article

Prognostic value of PET/CT with ¹⁸F-fluoroazomycin arabinoside for patients with head and neck squamous cell carcinomas receiving chemoradiotherapy

verfasst von: Tsuneo Saga, Masayuki Inubushi, Mitsuru Koizumi, Kyosan Yoshikawa, Ming-Rong Zhang, Takayuki Obata, Katsuyuki Tanimoto, Rintaro Harada, Takashi Uno, Yasuhisa Fujibayashi

Erschienen in: Annals of Nuclear Medicine | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

The prognostic value of positron emission tomography/computed tomography (PET/CT) with ¹⁸F-fluoroazomycin arabinoside (FAZA) was evaluated in patients with head and neck squamous cell carcinoma (HNSCC) who underwent chemoradiotherapy (CRT).

Methods

Twenty-nine patients with head and neck cancer underwent FAZA PET/CT before treatment. Data acquisition started 2 h after FAZA administration. In 26 patients with squamous cell carcinoma, FAZA uptakes by the primary lesions (tumor–muscle ratio in primary lesion: Pr T/M) and by the lymph node metastases (tumor–muscle ratio in lymph node metastasis) were compared with various clinical parameters. For the HNSCC patients who completed CRT protocol (n = 23), those who experienced disease progression were compared with those who did not experience disease progression with respect to the clinical and PET parameters. The prognostic values of the clinical and PET parameters were then evaluated with regard to progression-free survival (PFS).

Results

Pr T/M positively correlated with the lesion’s maximum diameter, and it was significantly higher in stage IV lesions compared with stage I–III lesions. No significant differences were observed between the patients who experienced disease progression and those who did not, with respect to the clinical parameters. The average Pr T/M tended to be higher in patients with disease progression, although the differences were not statistically significant (p = 0.086). Kaplan–Meier analysis with log-rank tests indicated that Pr T/M was an only significant predictor of PFS among PET and clinical parameters evaluated (p = 0.010).

Conclusions

FAZA uptake by the primary lesion was a significant prognostic indicator in HNSCC patients undergoing CRT. Hence, FAZA PET/CT may provide useful information in the management of HNSCC patients treated with CRT.

Registration number of clinical trial’s registry: UMIN000003440.

Brown JM. The hypoxic cell: a target for selective cancer therapy—eighteenth Bruce F. Cain memorial award lecture. Cancer Res. 1999;59:5863–70.PubMed

Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721–32.CrossRefPubMed

Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49:129S–48S.CrossRefPubMed

Nordsmark M, Overgaart M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 1996;41:31–9.CrossRefPubMed

Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhist MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38:285–9.CrossRefPubMed

Le QT, Kovacs MS, Dorie MJ, Koong A, Terris DJ, Pinto HA, et al. Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2003;56:375–83.CrossRefPubMed

Rajendran JG, Krohn KA. F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy. Semin Nucl Med. 2015;45:151–62.CrossRefPubMedPubMedCentral

Geets X, Grégoire V, Lee JA. Implementation of hypoxia PET imaging in radiation therapy planning. Q J Nucl Med Mol Imaging. 2013;57:271–82.PubMed

Mees G, Dierckx R, Vangestel C, Van de Wiele C. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging. 2009;36:1674–86.CrossRefPubMedPubMedCentral

10.

Lopci E, Grassi I, Chiti A, Nanni C, Cicoria G, Toschi L, et al. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am J Nucl Med Mol Imaging. 2014;4:365–84.PubMedPubMedCentral

11.

Lee ST, Scott AM. Hypoxia positron emission tomography imaging with ¹⁸F-fluoromisonidazole. Semin Nucl Med. 2007;37:451–61.CrossRefPubMed

12.

Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M, et al. FDG—a marker of tumour hypoxia? A comparison with [¹⁸F]fluoromisonidazole and pO₂-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging. 2006;33:1426–31.CrossRefPubMed

13.

Rajendran JG, Schwartz DL, O’Sullivan J, Peterson LM, Ng P, Scharnhorst J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435–41.CrossRefPubMedPubMedCentral

14.

Kumar P, Stypinski D, Xia H, McEwan AJB, Machulla HJ, Wiebe LI. Fluoroazomycin arabinoside (FAZA): synthesis, H-2 and H-3-labeling and preliminary biological evaluation of a novel 2-nitroimidazole marker of tissue hypoxia. J Label Compd Radiopharm. 1999;42:3–16.CrossRef

15.

Abolmaali N, Haase R, Koch A, Zips D, Steinbach J, Baumann M, et al. Two or four hour [¹⁸F]FMISO-PET in HNSCC. When is the contrast best? Nuklearmedizin. 2011;50:22–7.CrossRefPubMed

16.

Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-specific tumor imaging with ¹⁸F-fluoroazomycin arabinoside. J Nucl Med. 2005;46:106–13.PubMed

17.

Servagi-Vernat S, Differding S, Hanin FX, Labar D, Bol A, Lee JA, et al. A prospective clinical study of ¹⁸F-FAZA PET–CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. Eur J Nucl Med Mol Imaging. 2014;41:1544–52.CrossRefPubMed

18.

Bollineni VR, Kerner GS, Pruim J, Steenbackers RJ, Wieqman EM, Koole MJ, et al. PET imaging of tumor hypoxia using ¹⁸F-fluoroazomycin arabinoside in stage III–IV non-small cell lung cancer patients. J Nucl Med. 2013;54:1175–80.CrossRefPubMed

19.

Saga T, Inubushi M, Koizumi M, Yoshikawa K, Zhang MR, Tanimoto K, et al. Prognostic value of ¹⁸F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small cell lung cancer. Cancer Sci. 2015;106:1554–60.CrossRefPubMedPubMedCentral

20.

Garcia-Parra R, Wood D, Shah RB, Siddiqui J, Hussain H, Park H, et al. Investigation on tumor hypoxia in resectable primary prostate cancer as determined by ¹⁸F-FAZA PET/CT utilizing mutimodality fusion techniques. Eur J Nucl Med Mol Imaging. 2011;38:1816–23.CrossRefPubMedPubMedCentral

21.

Havelund BM, Holdgaard PC, Rafaelsen SR, Mortensen LS, Theil J, Bender D, et al. Tumour hypoxia imaging with ¹⁸F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer. Nucl Med Commun. 2013;34:155–61.CrossRefPubMed

22.

Hayashi K, Furutsuka K, Takei M, Muto M, Nakao R, Aki H, et al. High-yield automated synthesis of [¹⁸F]fluoroazomycin arabinoside ([¹⁸F]FAZA) for hypoxia-specific tumor imaging. Appl Radiat Isot. 2011;69:1007–13.CrossRefPubMed

23.

Souvatzoglou M, Grosu AL, Röper B, Krause BJ, Beck R, Reischl G, et al. Tumour hypoxia imaging with [¹⁸F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging. 2007;34:1566–75.CrossRefPubMed

24.

Grosu AL, Souvatzoglou M, Röper B, Dobritz M, Wiedenmann N, Jacob V, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:541–51.CrossRefPubMed

25.

Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol. 2012;105:14–20.CrossRefPubMed

26.

Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with ¹⁸F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253–60.PubMed

27.

Sato J, Kitagawa Y, Yamazaki Y, Hata H, Asaka T, Miyakoshi M, et al. Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:2031–41.CrossRefPubMed

Titel: Prognostic value of PET/CT with 18F-fluoroazomycin arabinoside for patients with head and neck squamous cell carcinomas receiving chemoradiotherapy
verfasst von: Tsuneo Saga
Masayuki Inubushi
Mitsuru Koizumi
Kyosan Yoshikawa
Ming-Rong Zhang
Takayuki Obata
Katsuyuki Tanimoto
Rintaro Harada
Takashi Uno
Yasuhisa Fujibayashi
Publikationsdatum: 12.12.2015
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 3/2016
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-015-1048-5

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

18F-FDG and 18F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes

Fluorine-18-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer after surgical resection: a systematic review and meta-analysis

Normal values and standardization of parameters in nuclear cardiology: Japanese Society of Nuclear Medicine working group database

Heterogeneity of intrahepatic fat distribution determined by 18F-FDG PET and CT

Comparison of integrated whole-body PET/MR and PET/CT: Is PET/MR alternative to PET/CT in routine clinical oncology?

Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma